Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for patients with solid tumors. Its primary program, ficerafusp alfa, is a first-in-class bifunctional antibody that integrates an epidermal growth factor receptor (EGFR)-directed monoclonal antibody with a transforming growth factor beta (TGF-β) binding domain. This design targets EGFR-expressing tumor cells while modulating TGF-β signaling in the tumor microenvironment to overcome fibrotic barriers, enhance immune cell penetration, and promote deeper anti-tumor responses. The therapy is being advanced in clinical trials for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), particularly HPV-negative cases with high unmet need, in combination with pembrolizumab. Evaluation is also underway in metastatic colorectal cancer, both as monotherapy and in combinations, highlighting its potential across multiple EGFR- and TGF-β-driven solid tumor indications. Incorporated in 2018 and headquartered in Boston, Massachusetts, Bicara Therapeutics Inc. operates within the biotechnology sector, emphasizing oncology innovation through targeted tumor microenvironment modulation.